Regeneron Pharmaceuticals REGN EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's EV / EBITDA?
- Regeneron Pharmaceuticals (REGN) reported EV / EBITDA of 19.5× in Q1 2026.
- How has Regeneron Pharmaceuticals's EV / EBITDA changed year-over-year?
- Regeneron Pharmaceuticals's EV / EBITDA increased by 22.5% year-over-year, from 15.9× to 19.5×.
- What is the long-term trend for Regeneron Pharmaceuticals's EV / EBITDA?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's EV / EBITDA has grown at a 14.4% compound annual growth rate (CAGR), from 36.7× to 62.9×.
- What does EV / EBITDA mean?
- What the whole business (debt included) costs relative to its operating cash earnings.
- How do you interpret EV / EBITDA?
- Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
- How does EV / EBITDA compare across companies?
- Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.